This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)

Tipranks - Tipranks - Fri Jul 31, 5:26AM CDT

Analysts fell to the sidelines weighing in on Boston Scientific (BSX) and Capricor Therapeutics (CAPR) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Claim 55% Off TipRanks

Boston Scientific (BSX)

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Boston Scientific yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $46.04.

According to TipRanks.com, Biegelsen is a 4-star analyst with an average return of 2.5% and a 50.7% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $67.89, which is a 59.1% upside from current levels. In a report issued on July 14, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $49.00 price target.

See the top stocks recommended by analysts >>

Capricor Therapeutics (CAPR)

Capricor Therapeutics received a Hold rating from H.C. Wainwright analyst Joseph Pantginis today. The company’s shares closed last Tuesday at $6.57, close to its 52-week low of $3.52.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 21.1% and a 51.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, NewAmsterdam Pharma Company, and Cadrenal Therapeutics, Inc. ;'>

Currently, the analyst consensus on Capricor Therapeutics is a Moderate Buy with an average price target of $18.64, implying a 174.9% upside from current levels. In a report issued on July 28, B. Riley Securities also downgraded the stock to Hold with a $10.00 price target.

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).